[Levosimendan in acute heart failure: past, present and future].
نویسنده
چکیده
Acute heart failure (AHF) is one of the main causes of cardiovascular morbidity and mortality. After diagnosis of AHF and during the first year of followup, 45% of the patients will be admitted to hospital at least once and mortality can be as high as 40%.1 Therapeutic approaches are therefore needed to alleviate symptoms, stabilize the hemodynamics of the patients, and improve their quality of life and survival. Interest in clinical investigation in the field of AHF is very recent. Thus, unlike chronic heart failure, the scientific evidence to support therapeutic action is not extensive. In fact, the first clinical guidelines for management of AHF were not published until 2005.1
منابع مشابه
Levosimendan in Patients with Left Heart Failure After Acute Myocardial Infarction - Review of the RUSSLAN Study and Future Developments with Levosimendan
متن کامل
The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
In the present review striking data showing that intensive care unit patients with acute heart failure and high-risk surgical patients may markedly benefit from the use of levosimendan are presented. Indeed, levosimendan is an effective new agent that acts via two complementary mechanisms. It enhances cardiac contractility by improving the response of the myofilaments to intracellular calcium, ...
متن کاملLevosimendan: current data, clinical use and future development
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. The principal pharmacological effects of levosimendan are (a) increased cardiac contractility by calcium sensitisation of troponin C, (b) vasodilation, and (c) cardioprotection. These last two effects...
متن کاملLevosimendan: current status and future prospects.
PURPOSE OF REVIEW While patients with acute heart failure typically receive diuretics and vasodilators, contractile dysfunction and peripheral hypoperfusion also leads to a widespread use of inotropic agents despite the lack of evidence for efficacy or safety. Levosimendan, a calcium sensitizer and vasodilator, has been proposed to be superior to standard inotropes. In addition, further possibl...
متن کاملLevosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
AIMS Many chronic heart failure (CHF) patients take beta-blockers. When such patients are hospitalized for decompensation, it remains unclear how ongoing beta-blocker treatment will affect outcomes of acute inotrope therapy. We aimed to assess outcomes of SURVIVE patients who were on beta-blocker therapy before receiving a single intravenous infusion of levosimendan or dobutamine. METHODS AND...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Revista espanola de cardiologia
دوره 59 4 شماره
صفحات -
تاریخ انتشار 2006